COVID-19 outcomes in patients taking cardioprotective medications.

Fritha J MorrisonMaxwell SuAlexander Turchin

Published in: PloS one (2022)

Cardioprotective medications were not associated with a consistent benefit in COVID-19. As vaccination and effective treatments are not yet universally accessible worldwide, research should continue to determine whether affordable and widely available medications could be utilized to decrease the risks of this disease.

Keyphrases

coronavirus disease
sars cov
end stage renal disease

ejection fraction
newly diagnosed

metabolic syndrome
type diabetes

human health
insulin resistance